Get the Stockscreener App
3.33
4.58%
-0.16
Pre-market:
3.29
-0.04
-1.20%
Eledon Pharmaceuticals Inc stock is traded at $3.33, with a volume of 1.93M.
It is down -4.58% in the last 24 hours and up +28.08% over the past month.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
See More
Previous Close:
$3.49
Open:
$3.46
24h Volume:
1.93M
Relative Volume:
1.84
Market Cap:
$199.41M
Revenue:
-
Net Income/Loss:
$-40.33M
P/E Ratio:
-1.8603
EPS:
-1.79
Net Cash Flow:
$-39.53M
1W Performance:
+21.53%
1M Performance:
+28.08%
6M Performance:
-1.48%
1Y Performance:
+5.21%
1-Day Range:
$3.26
$3.505
1-Week Range:
$2.745
$3.76
52-Week Range:
$2.315
$5.54
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Name
Eledon Pharmaceuticals Inc
Sector
Industry
Phone
949-238-8090
Address
19800 MACARTHUR BLVD., IRVINE
Compare ELDN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
3.33 | 208.99M | 0 | -40.33M | -39.53M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.44 | 109.29B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.90 | 62.13B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.74 | 61.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
814.17 | 51.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
313.54 | 34.68B | 4.56B | -176.77M | 225.30M | -1.7177 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Guggenheim | Buy |
| May-13-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-23-21 | Initiated | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Stock (ELDN) Latest News
What technical models suggest about Eledon Pharmaceuticals Inc.’s comebackWeekly Stock Analysis & Weekly Top Gainers Trade List - newser.com
Will Eledon Pharmaceuticals Inc. (2TK) stock test record highs in 2025Market Risk Analysis & Long-Term Safe Investment Plans - newser.com
Is this a good reentry point in Eledon Pharmaceuticals Inc.Portfolio Value Summary & Accurate Buy Signal Alerts - newser.com
Will breakout in Eledon Pharmaceuticals Inc. lead to full recoveryQuarterly Profit Summary & Real-Time Buy Zone Alerts - newser.com
Eledon Pharmaceuticals Inc. stock daily chart insightsProduct Launch & High Return Stock Watch Alerts - newser.com
Real time pattern detection on Eledon Pharmaceuticals Inc. stock2025 Trade Ideas & High Win Rate Trade Tips - newser.com
Is Eledon Pharmaceuticals Inc. (2TK) stock inflation resilientWeekly Gains Report & Verified Swing Trading Watchlist - newser.com
What analysts say about Eledon Pharmaceuticals Inc stockBull Market Opportunities & High Profit Portfolio Growth - earlytimes.in
Has Eledon Pharmaceuticals Inc. formed a bullish divergenceJuly 2025 Analyst Calls & Expert Approved Momentum Ideas - newser.com
Published on: 2025-10-21 12:33:22 - newser.com
Can Eledon Pharmaceuticals Inc. (2TK) stock double in coming yearsLong Setup & Technical Pattern Alert System - newser.com
How to build a dashboard for Eledon Pharmaceuticals Inc. stockGDP Growth & Fast Gain Stock Trading Tips - newser.com
What dividend safety rating applies to Eledon Pharmaceuticals Inc. (2TK) stockTreasury Yields & Safe Swing Trade Setup Alerts - newser.com
Eledon Pharmaceuticals Inc. stock chart pattern explainedPortfolio Risk Report & AI Driven Price Predictions - newser.com
Published on: 2025-10-20 20:13:45 - newser.com
How strong is Eledon Pharmaceuticals Inc. (2TK) stock earnings growthPrice Action & Reliable Volume Spike Trade Alerts - newser.com
Insider Buy: Is Eledon Pharmaceuticals Inc. (2TK) stock overpriced at current multiplesLong Setup & AI Forecasted Entry and Exit Points - nchmf.gov.vn
Will Eledon Pharmaceuticals Inc. stock return to pre crisis levelsRecession Risk & Real-Time Market Trend Scan - newser.com
Why Eledon Pharmaceuticals Inc. (2TK) stock trades below fair valueShare Buyback & Verified Momentum Stock Ideas - newser.com
Is Eledon Pharmaceuticals Inc. stock a buy in volatile marketsMarket Performance Summary & Low Risk High Win Rate Stock Picks - newser.com
What risks investors should watch in Eledon Pharmaceuticals Inc. stockJuly 2025 Weekly Recap & Daily Chart Pattern Signal Reports - Trung tâm Dự báo KTTV quốc gia
Is Eledon Pharmaceuticals Inc. stock safe for conservative investorsJuly 2025 Analyst Calls & Free High Return Stock Watch Alerts - nchmf.gov.vn
Will Eledon Pharmaceuticals Inc. stock outperform Nasdaq indexWeekly Stock Analysis & Long-Term Growth Plans - nchmf.gov.vn
Will Eledon Pharmaceuticals Inc. stock gain from lower inflationRate Cut & Technical Pattern Recognition Alerts - newser.com
What hedge fund activity signals for Eledon Pharmaceuticals Inc. stock2025 Volume Leaders & Safe Capital Investment Plans - nchmf.gov.vn
With 51% ownership in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN), institutional investors have a lot riding on the business - simplywall.st
Can Eledon Pharmaceuticals Inc. stock surprise with earnings upsideQuarterly Portfolio Report & AI Powered Trade Plan Recommendations - nchmf.gov.vn
Why Eledon Pharmaceuticals Inc. (2TK) stock stays undervaluedInsider Buying & Community Verified Trade Signals - nchmf.gov.vn
Eledon to present kidney transplant rejection drug results at ASN meeting - Investing.com India
Why Eledon Pharmaceuticals Inc. stock could see breakout soonSwing Trade & Fast Gaining Stock Strategy Reports - nchmf.gov.vn
Eledon Pharmaceuticals Inc Stock (ELDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.71%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):